With the development of novel antibody-drug conjugates(ADC)such as T-DXd(trastuzumab deruxtecan)and HER3-DXd(patritumab deruxtecan),global tumor cell targeting has become possible beyond the human epidermal growth fac...With the development of novel antibody-drug conjugates(ADC)such as T-DXd(trastuzumab deruxtecan)and HER3-DXd(patritumab deruxtecan),global tumor cell targeting has become possible beyond the human epidermal growth factor receptor(HER)2-positive setting[1,2].Both drugs offer promising options for individualized treatment targeting HER2 and HER3 expression,potentially even in tumors which are currently considered“HER2-negative”.展开更多
文摘With the development of novel antibody-drug conjugates(ADC)such as T-DXd(trastuzumab deruxtecan)and HER3-DXd(patritumab deruxtecan),global tumor cell targeting has become possible beyond the human epidermal growth factor receptor(HER)2-positive setting[1,2].Both drugs offer promising options for individualized treatment targeting HER2 and HER3 expression,potentially even in tumors which are currently considered“HER2-negative”.
